Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID-19 pandemic lockdowns: A large cohort.
Dana BarequetReut ShorOri SegalEran GreenbaumOmer TrivizkiAnat LoewensteinGilad RabinaPublished in: Acta ophthalmologica (2023)
During the COVID-19 period, patients were treated with significantly less intravitreal anti-VEGF injection compared to the previous year with compensation in the following year. These changes in treatment patterns did not have a significant impact on BCVA outcomes. Age, gender, baseline BCVA and number of injections are predictors of final visual outcomes.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- sars cov
- coronavirus disease
- vascular endothelial growth factor
- metabolic syndrome
- endothelial cells
- diabetic retinopathy
- patient reported outcomes
- adipose tissue
- skeletal muscle
- ultrasound guided
- platelet rich plasma
- patient reported
- age related macular degeneration
- weight loss
- replacement therapy
- combination therapy